GEXVal Inc. is a Japanese-based spinoff company from Takeda Pharmaceutical Company Limited, established since April 2018. We focus on rare/intractable diseases to help patients and families who need better treatment options fighting against debilitating diseases. Our mission is to execute late-stage research and early development projects with agility and taking risks in true spirit of entrepreneurship to deliver medicines in areas of high medical need. We are loaded with 2 development candidate and 3 discovery projects.
Our strategy is to Generate EXtra Value by creative repositioning and extensive external partnership to accelerate R&D process: 1) by multi-platform drug repositioning research of novel development candidate molecules to aim high R&D productivity, 2) by focusing on rare/intractable diseases, and 3) by focusing on GPCR modulators, known as drugs with higher chance of success.
This is GEXVal Inc., who always consider patients first and are committed to deliver.
Our strategy is to Generate EXtra Value by creative repositioning and extensive external partnership to accelerate R&D process: 1) by multi-platform drug repositioning research of novel development candidate molecules to aim high R&D productivity, 2) by focusing on rare/intractable diseases, and 3) by focusing on GPCR modulators, known as drugs with higher chance of success.
This is GEXVal Inc., who always consider patients first and are committed to deliver.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Japan
Year Founded:
2018
Main Therapeutic Focus:
Orphan/Rare Diseases
Lead Product in Development:
GXV-001/Neuroscience rare disease
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
